Overexpression of TMEM158 contributes to ovarian carcinogenesis

Journal of Experimental & Clinical Cancer Research

Xiaoyan Qu¹  Weihong Yang¹  Ning Luo¹  Li Chen¹  Jing Guo¹  Zhongping Cheng¹ 

[1] Institute of Gynecological Minimally Invasive Medicine, Tongji University School of Medicine, Shanghai 200090, China

关键词: Cell adhesion;    TGF-β;    Cell invasion;    Ovarian cancer;    TMEM158;   

Others  :  1226288
DOI  :  10.1186/s13046-015-0193-y

 received in 2015-04-28, accepted in 2015-07-17,  发布年份 2015

【 摘 要 】

Background

Transmembrane protein 158 (TMEM158) is a recently identified upregulated gene during Ras-induced senescence. Its association with various cancers has been recently reported. However, the expression and biological function of TMEM158 in ovarian cancer is still unclear. This study was aimed to elucidate the roles of TMEM158 in cell proliferation, adhesion and cell invasion of ovarian cancer cells.

Methods

We analyzed TMEM158 mRNA level in ovarian cancer tissues and adjacent no-tumorous tissues by real-time PCR. We then suppressed TMEM158 expression of ovarian cancer cells by RNA interference and examined the effects of TMEM158 knockdown on cancerous transformation of ovarian cancer cells.

Results

The RNA-sequencing data of the ovarian cancer cohort from The Cancer Genome Atlas project (TCGA) and our real-time PCR data showed that TMEM158 was overexpressed in ovarian cancer. Knockdown of TMEM158 by RNA interference in ovarian cancer cells significantly inhibited cell proliferation, which may be due to the increase of G1-phase arrest. Silencing of TMEM158 also inhibited cell adhesion, cell invasion as well as tumorigenicity in nude mice. Moreover, knockdown of TMEM158 notably repressed cell adhesion via down-regulating the expression intercellular adhesion molecule1 (ICAM1) and vascular cell adhesion molecule1 (VCAM1). Transforming Growth Factor-β (TGF-β) signaling pathway was also remarkably impaired by TMEM158 silencing.

Conclusions

Our data suggests that TMEM158 may work as an oncogene for ovarian cancer and that inhibition of TMEM158 may be a therapeutic strategy for ovarian cancer.

【 授权许可】

   
2015 Cheng et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

【 参考文献 】

• [1]Zeinoun Z, Teugels E, De Bleser PJ, Neyns B, Geerts A, De Greve J: Insufficient TGF-beta 1 production inactivates the autocrine growth suppressive circuit in human ovarian cancer cell lines. Anticancer Res 1999, 19(1a):413-20.
• [2]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96.
• [3]Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni JF Jr: Recent cancer trends in the United States. J Natl Cancer Inst 1995, 87(3):175-82.
• [4]Chuffa LGA, Fioruci-Fontanelli BA, Mendes LO, Fávaro WJ, Pinheiro PFF, Martinez M, et al.: Characterization of chemically induced ovarian carcinomas in an ethanol-preferring rat model: influence of long-term melatonin treatment. 2013.
• [5]Chuffa LG, Fioruci-Fontanelli BA, Mendes LO, Seiva FRF, Martinez M, Fávaro WJ, et al.: Melatonin attenuates the TLR4-mediated inflammatory response through MyD88-and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer. BMC Cancer 2015, 15(1):34. BioMed Central Full Text
• [6]Noorani L, Stenzel M, Liang R, Pourgholami MH, Morris DL: Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model. J Nanobiotechnol 2015, 13(1):25. BioMed Central Full Text
• [7]Kim A, Ueda Y, Naka T, Enomoto T: Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 2012, 31:14. BioMed Central Full Text
• [8]Barradas M, Gonos ES, Zebedee Z, Kolettas E, Petropoulou C, Delgado MD, et al.: Identification of a candidate tumor-suppressor gene specifically activated during Ras-induced senescence. Exp Cell Res 2002, 273(2):127-37.
• [9]Sussan TE, Pletcher MT, Murakami Y, Reeves RH: Tumor suppressor in lung cancer 1 (TSLC1) alters tumorigenic growth properties and gene expression. Mol Cancer 2005, 4:28. BioMed Central Full Text
• [10]Iglesias D, Fernandez-Peralta AM, Nejda N, Daimiel L, Azcoita MM, Oliart S, et al.: RIS1, a gene with trinucleotide repeats, is a target in the mutator pathway of colorectal carcinogenesis. Cancer Genet Cytogenet 2006, 167(2):138-44.
• [11]Verlinden I, Janssens J, Raus J, Michiels L: Microdissection and SAGE as a combined tool to reveal gene expression in ductal carcinoma in situ of the breast. Mol Carcinog 2004, 41(4):197-206.
• [12]Zirn B, Samans B, Wittmann S, Pietsch T, Leuschner I, Graf N, et al.: Target genes of the WNT/beta-catenin pathway in Wilms tumors. Genes Chromosomes Cancer 2006, 45(6):565-74.
• [13]Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al.: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102(43):15545-50.
• [14]Guo J, Chen L, Luo N, Yang W, Qu X, Cheng Z: Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells. Oncol Rep 2015, 33(6):3124-30.
• [15]Silletti S, Paku S, Raz A: Autocrine motility factor and the extracellular matrix. I. Coordinate regulation of melanoma cell adhesion, spreading and migration involves focal contact reorganization. Int J Cancer 1998, 76(1):120-8.
• [16]Yang XJ, Li J, Sun CX, Zheng FY, Hu LN: The effect of high frequency steep pulsed electric fields on in vitro and in vivo antitumor efficiency of ovarian cancer cell line skov3 and potential use in electrochemotherapy. J Exp Clin Cancer Res 2009, 28:53. BioMed Central Full Text
• [17]Evan GI, Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411(6835):342-8.
• [18]Molinari M: Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 2000, 33(5):261-74.
• [19]Nieto M, Barradas M, Criado LM, Flores JM, Serrano M, Llano E: Normal cellular senescence and cancer susceptibility in mice genetically deficient in Ras-induced senescence-1 (Ris1). Oncogene 2007, 26(12):1673-80.
• [20]Shi Y, Massague J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113(6):685-700.
• [21]Wakefield LM, Roberts AB: TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002, 12(1):22-9.
• [22]Li GC, Ye QH, Dong QZ, Ren N, Jia HL, Qin LX: TGF beta1 and related-Smads contribute to pulmonary metastasis of hepatocellular carcinoma in mice model. J Exp Clin Cancer Res 2012, 31:93. BioMed Central Full Text
• [23]Deng H, Makizumi R, Ravikumar TS, Dong H, Yang W, Yang WL: Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res 2007, 313(5):1033-44.
• [24]Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, et al.: Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett 2010, 291(1):59-66.
• [25]Staal-van den Brekel AJ, Thunnissen FB, Buurman WA, Wouters EF: Expression of E-selectin, intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 in non-small-cell lung carcinoma. Virchows Arch 1996, 428(1):21-7.
• [26]Maurer CA, Friess H, Kretschmann B, Wildi S, Muller C, Graber H, et al.: Over-expression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer. Int J Cancer 1998, 79(1):76-81.
• [27]Banks RE, Gearing AJ, Hemingway IK, Norfolk DR, Perren TJ, Selby PJ: Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer 1993, 68(1):122-4.
• [28]Alexiou D, Karayiannakis AJ, Syrigos KN, Zbar A, Kremmyda A, Bramis I, et al.: Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer 2001, 37(18):2392-7.
• [29]Rosette C, Roth RB, Oeth P, Braun A, Kammerer S, Ekblom J, et al.: Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 2005, 26(5):943-50.